Assessment of the Functional Status of Patients with Ischaemic Stroke Receiving Thrombolytic Treatment
DOI:
https://doi.org/10.15225/PNN.2020.9.1.2Keywords
stroke, thrombolysis, functional statusAbstract
Introduction. Intravenous thrombolysis is a gold standard in the treatment of acute ischaemic stroke. It causes reperfusion in the region of ischaemia and as a result it has a positive effect on functional outcomes of patients. The sooner this treatment is introduced the higher efficacy can be expected.
Aim. The study objective was to assess the functional status of patients with ischaemic stroke, undergoing thrombolytic treatment and the incidence of thrombolysis complications.
Material and Methods. Retrospective studies were conducted on a group of 109 patients hospitalised due to ischaemic cerebral stroke and qualified for thrombolytic treatment. The functional status was assessed with the use of the modified Rankin Scale and National Institutes of Health Stroke Scales on admission and discharge day. The study group included 55 males and 54 females (respectively: 50.5% and 49.5% of the total study population). The subject age was between 32 and 96 years, with the mean age of 69.8.
Results. The average time between the onset of symptoms and initiation of thrombolytic treatment was 182 minutes. The National Institutes of Health Stroke Scale at the moment of qualification for treatment was 10.11 points, and the Rankin Scale was 2.88 points. On the day of discharge, the values were 5.81 and 2.05, respectively. A statistically significant (p < 0.0001) improvement in the functional status was observed in the group of patients who had no intra cerebral haemorrhage after thrombolysis. The most common complication of thrombolytic treatment was haemorrhagic transformation of the ischaemic stroke focus — 27 cases (24.77%). Death occurred in 9 subjects (8.26% of total), including 6 cases in males (10.91% of males) and was related to haemorrhagic transformation of the ischaemic stroke focus (p = 0.000).
Conclusions. The implemented treatment of stroke resulted in improvement of the functional status. The most frequent complication was haemorrhagic conversion of stroke. (JNNN 2020;9(1):12–19)
References
Siebert J., Nyka W.M. (Red.), Udar mózgu. Postępowanie diagnostyczne i terapia w ostrym okresie udaru. Wyd. Via Medica, Gdańsk 2007.
Jauch E.C., Saver J.L., Adams Jr H.P. et al. Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.
Davis S., Donnan G.A. Time Is Penumbra: Imaging, Selection and Outcome. The Johann Jacob Wepfer Award 2014. Cerebrovasc Dis. 2014;38(1):59–72.
Donnan G.A., Baron J.-C., Davis S.M., Sharp F.R. The Ischemic Penumbra: Overview, Definition, and Criteria. In Donnan G.A., Baron J.-C., Davis S.M., Sharp F.R. (Eds.), The Ischemic Penumbra. Pathophysiology, Imaging and Therapy. Informa Healthcare, New York–London 2007;7–20.
Członkowska A., Kobayashi A. Postępowanie w udarze mózgu — wytyczne Grupy Ekspertów Sekcji Chorób Naczyniowych Polskiego Towarzystwa Neurologicznego. Aktualizacja 2013: leczenie trombolityczne. Neurol Neuroch Pol. 2013;47(4):303–309.
Kozera G., Sobolewski P., Serafin Z. Doświadczenie dwóch dekad leczenia trombolitycznego udaru niedokrwiennego mózgu. Aktualne pytania i odpowiedzi. Wyd. AsteriaMed, Gdańsk 2017.
Powers W.J., Rabinstein A.A., Ackerson T. et al. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–e110.
Hacke W., Kaste M., Bluhmki E. et al. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N Engl J Med. 2008;359(13):1317–1329.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med. 1995;333(24):1581–1587.
Albers G.W., Bates V.E., Clark W.M., Bell R., Verro P., Hamilton S.A. Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA. 2000;283(9):1145–1150.
Hill M.D., Buchan A.M., Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005;172(10):1307–1312.
Wahlgren N., Ahmed N., Dávalos A. et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–282.
Lokeskrawee T., Muengtaweepongsa S., Patumanond J. et al. Prediction of Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke: The Symptomatic Intracranial Hemorrhage Score. J Stroke Cerebrovasc Dis. 2017;26(11):2622–2629.
del Zoppo G.J., Poeck K., Pessin M.S. et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32(1):78–86.
Engelter S.T., Fluri F., Buitrago-Téllez C. et al. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J Neurol. 2005;252(10):1167–1170.
Hill M.D., Lye T., Moss H. et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology. 2003;60(9):1525–1527.
Filipska K., Skrzypek-Czerko M., Cwiekala-Lewis K., Ślusarz R. Clinimetric Evaluation of Functional Capacity and Quality of Life of Stroke Patients — Study Review. J Neurol Neurosurg Nurs. 2019;8(2):86–90.
Raciborski F., Gujski M. (Red.), Udary mózgu — rosnący problem w starzejącym się społeczeństwie. Raport Instytutu Ochrony Zdrowia, Warszawa 2016.
Gurański K., Zięba T., Kowalczyk L., Podemski R. Analiza leczenia trombolitycznego u chorych z niedokrwiennym udarem mózgu na podstawie własnych doświadczeń. Udar Mózgu. 2007;9(2):47–51.
Rosińczuk J., Bonk K., Kołtuniuk A. Analysis of thrombolytic therapy in ischemic stroke treatment. Ann Acad Med Siles. 2015;69:125–131.
Owe J.F., Sanaker P.S., Naess H., Thomassen L. The yield of expanding the therapeutic time window for tPA. Acta Neurol Scand. 2006;114(5):354–357.
Alderazi Y.J., Chang J., Yang J.P. et al. Impact of Protocol Deviations in Acute Ischemic Stroke Treated with Intravenous rt-PA within 4.5 Hours after Symptom Onset. Neurohospitalist. 2012;2(3):82–86.
Roje-Bedeković M., Vargek-Solter V., Corić L. et al. Thrombolysis for Acute Ischemic Stroke — Our Experiences as Part of SITS-MOST. Acta Clin Croat. 2009;48(3):287–293.
Walters M.R., Muir K.W., Harbison J., Lees K.R., Ford G.A. Intravenous Thrombolysis for Acute Ischaemic Stroke: Preliminary Experience with Recombinant Tissue Plasminogen Activator in the UK. Cerebrovasc Dis. 2005;20(6):438–442.
Hacke W., Donnan G., Fieschi C. et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–774.
Litwin T., Kobayashi A., Skowrońska M., Członkowska A. Thrombolysis in acute ischaemic stroke within 3 hours of symptom onset: A report of the first 100 cases. Neurol Neuroch Pol. 2008;42(1):1–5.
Wahlgren N., Ahmed N., Dávalos A. et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–282.
Wawrzyńczyk M., Pierzchała K., Łabuz-Roszak B. Thrombolysis in stroke — 8 years of experience. Ann Acad Med Siles. 2012;66(6):37–44.
Jabłońska R., Wronkowska A., Ślusarz R., Filipska K., Meder G., Sokal P. Endovascular and Thrombolytic Therapy and the Functional Status of Patients after Ischemic Stroke. J Neurol Neurosurg Nurs. 2019;8(2):69–77.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 279
Number of citations: 0